0001209191-17-021860.txt : 20170320
0001209191-17-021860.hdr.sgml : 20170320
20170320194211
ACCESSION NUMBER: 0001209191-17-021860
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170317
FILED AS OF DATE: 20170320
DATE AS OF CHANGE: 20170320
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Flexion Therapeutics Inc
CENTRAL INDEX KEY: 0001419600
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 10 MALL ROAD
STREET 2: SUITE 301
CITY: BURLINGTON
STATE: MA
ZIP: 01803
BUSINESS PHONE: (781) 305-7777
MAIL ADDRESS:
STREET 1: 10 MALL ROAD
STREET 2: SUITE 301
CITY: BURLINGTON
STATE: MA
ZIP: 01803
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Bodick Neil
CENTRAL INDEX KEY: 0001598099
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36287
FILM NUMBER: 17702666
MAIL ADDRESS:
STREET 1: C/O FLEXION THERAPEUTICS, INC.
STREET 2: 10 MALL ROAD, SUITE 301
CITY: BURLINGTON
STATE: MA
ZIP: 01803
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-03-17
0
0001419600
Flexion Therapeutics Inc
FLXN
0001598099
Bodick Neil
C/O FLEXION THERAPEUTICS, INC.
10 MALL ROAD, SUITE 301
BURLINGTON
MA
01803
0
1
0
0
Chief Medical Officer
Common Stock
2017-03-17
4
S
0
5000
20.4077
D
50937
D
Common Stock
388683
I
By Versant Development Fund III, LLC
Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted December 17, 2014.
The weighted average sale price for the transaction reported was $20.4077, and the range of prices were between $20.04 and $20.97. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Shares held by Versant Development Fund III, LLC. The Reporting Person is a manager and minority member of Versant Development Fund III, LLC. The Reporting Person disclaims any beneficial ownership of the shares held by Versant Development Fund III, LLC except to the extent of his pecuniary interest in these shares.
/s/ Frederick Driscoll, Attorney-in-Fact
2017-03-20